CU71 / Curacle - LARVOL DELTA

Basic Science and Pathogenesis. (PubMed, Alzheimers Dement) - "Our findings demonstrate that CU71 treatment ameliorates cognitive impairment by inhibiting BBB dysfunction and neuroinflammation in the 5XFAD mouse model of Alzheimer's disease."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Inflammation • GFAP

Curacle files international patent for Alzheimer's disease treatment 'CU71' [Google translation] (BioTimes) - "This international patent application is for a patent for the use of Alzheimer's disease, and is explained as a measure to secure the rights to the treatment in major countries around the world, following the application for a material patent last July."

Patent • Alzheimer's Disease

Curacle, 'CU71' PCT International Patent Application… Strengthening Global Rights [Google translation] (Medipana) - "Curacle...announced on the 23rd that it has applied for a PCT international patent for its Alzheimer's disease treatment candidate 'CU71'...The PCT (Patent Cooperation Treaty) international patent application is a system that can be applied for in approximately 150 countries at the same time, and can enter the examination stage in each country within a maximum of 30 months from the date of application....Through this application, Curacle is seeking to secure global rights, including major advanced countries such as the US, Europe, and Japan. These countries are rapidly aging and the social and economic burden of Alzheimer's disease is increasing, so the medical demand and marketability for related treatments are considered very high."

Patent • Alzheimer's Disease

Curacle Announces Preclinical Results of CU71, a Candidate for Alzheimer's Treatment [Google translation] (HIT News) - "Curacle...announced on the 15th that it will present the preclinical results of its Alzheimer's disease treatment candidate CU71 in a poster format at the 'Alzheimer's Association International Conference (AAIC 2025, Alzheimer's Association International Conference)' to be held in Toronto, Canada from the 27th to the 31st....Curacle explained that in an experiment using 5xFAD mice, a representative Alzheimer's disease animal model, CU71 showed superior cognitive function improvement and long-term memory recovery effects compared to the control drug donepezil. Significant differences were observed in both the object recognition experiment and the water maze experiment, and pathological analysis also confirmed changes such as reduced amyloid beta accumulation, suppression of neuroinflammation, increased expression of vascular endothelial junction proteins (ZO-1, Claudin5), and reduced RAGE expression."

Preclinical • Alzheimer's Disease

Curacle, Shareholder Allocation Paid-in Capital Increase Decision… Expected Value Increase Through Progress in R&D Development of Major Pipelines such as CU06 and CU71 [Google translation] (Hankyung) - "Curacle...held a board meeting on the 16th and decided to increase capital through a public offering of common stock after allocating a total of 28.6 billion won to shareholders. The number of shares to be issued is 7 million, which is approximately 50% of the current number of issued shares...Curacle plans to focus the funds secured through this paid-in capital increase on R&D costs and operating funds for its main pipelines. The main uses are: Clinical phase 2b for retinal disease treatment drug CU06, Clinical phase 1 for Alzheimer's disease treatment drug CU71, and R&D progress for main pipelines such as CU01, MT-101, and MT-103....CU06 is a first-in-class new drug candidate under development as an oral retinal disease treatment, and is preparing to apply for an IND (clinical trial plan) for a phase 2b clinical trial in the second half of this year."

Financing • New P2b trial • Alzheimer's Disease • Diabetic Nephropathy • Retinal Disorders

Curacle, CU71 First Unveiled at Bio Korea… Expanding Pharmaceutical Company Partnerships [Google translation] (HIT News) - "Curacle...announced on the 16th that it attended 'BIO KOREA 2025' held at COEX in Seoul last week and actively partnered with domestic and foreign pharmaceutical companies and investment firms focusing on major new drug pipelines...At this event, Curacle unveiled CU71, a new drug candidate currently under development as an Alzheimer's disease treatment, on the partnering stage for the first time....The company plans to continue follow-up discussions, including technology consultations and joint development."

Pipeline update • Alzheimer's Disease

The secret behind Curacle 'CU71', a treatment that has caught the attention of Alzheimer's specialists [Google translation] (HIT News) - "The next Alzheimer's treatment candidate that doctors are paying attention to may be found not in the brain itself, but in the 'blood vessels' surrounding the brain. Recently, industry experts have begun to pay attention to Curacle's new drug candidate 'CU71' as a realistic alternative that can overcome the limitations of expensive antibody treatments...Curacle is currently conducting additional preclinical trials for CU71 and plans to have a Pre-IND meeting with the US FDA in late 2025. It is expected to enter full-scale phase 1 clinical trials in the first half of 2026....The preclinical results of CU71 will be revealed for the first time at the 'Alzheimer's Association International Conference (AAIC 2025)' to be held in Toronto, Canada in July."

FDA event • New P1 trial • Preclinical • Alzheimer's Disease

Curacle to Present Preclinical Data for Alzheimer’s Treatment ’CU71’ at AAIC 2025 [Google translation] (Newspim) - "Curacle...announced on the 8th that it will present the preclinical data of its Alzheimer's treatment candidate 'CU71' through a poster at the 'Alzheimer's Association International Conference (AAIC) 2025' to be held in Toronto, Canada from July 27th to 31st....The data to be presented will include preclinical efficacy results showing that CU71 improves cognitive function decline by alleviating major pathological causes such as blood-brain barrier (BBB) dysfunction, neuroinflammatory response, and amyloid beta accumulation in an Alzheimer's disease animal model (5xFAD)....Meanwhile, Curacle is pushing forward with a US FDA Pre-IND meeting within the year to enter clinical trials for CU71, and is accelerating development with the goal of entering phase 1 clinical trials in the first half of 2026."

New P1 trial • Preclinical • Alzheimer's Disease